SCHEMBL336083

SCHEMBL336083

CCN(CC)c1ccc(C(=O)NC(c2cc(OC)cc(OC)c2)C(O)C(=O)Nc2ccc3nc(N)[nH]c3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F9 P00740 2/20 0.41
F7 P08709 2/20 0.41
MAPT P10636 5/20 0.40
DGAT1 O75907 1/20 0.39
F11 P03951 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SLC2A1 P11166 1/20 0.38
ESRRG P62508 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
ATM Q13315 1/20 0.37
METAP2 P50579 1/20 0.37
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
IKBKB O14920 1/20 0.36
FPR2 P25090 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335303 0.89 MAPT (0.40) F9F7MAPTESRRGLMNA
SCHEMBL335484 0.89 MAPT (0.43) F9F7MAPTSMN1; SMN2IKBKB
SCHEMBL337002 0.88 MAPT (0.41) F9F7MAPTESRRGLMNA
SCHEMBL336055 0.88 MAPT (0.46) F9F7MAPTF11MEN1
SCHEMBL335611 0.88 F9 (0.42) F9F7MAPTDGAT1F11
SCHEMBL335756 0.88 METAP2 (0.40) MAPTMEN1KMT2AESRRGKDM4E
SCHEMBL335968 0.86 MAPT (0.41) F9F7MAPTDGAT1MEN1
SCHEMBL335848 0.86 MCHR1 (0.42) F9F7MAPTESRRGSMN1; SMN2
SCHEMBL336687 0.85 MAPT (0.39) F9F7MAPTDGAT1MEN1
SCHEMBL335191 0.84 MAPT (0.45) F9F7MAPTDGAT1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
CN-101516834-A Isoserine derivatives for use as coagulation factor ixa inhibitors SANOFI AVENTIS (FR) 2009-08-26 CN claimed
CN-1359423-A Herbicide resistant plants HINZENTA CO LTD (GB) 2002-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 F9 3/4885F7 6/4885MAPT 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.